Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Endonovo Therapeutics (ENDV) Return on Sales (2016 - 2023)

Endonovo Therapeutics has reported Return on Sales over the past 11 years, most recently at 504.06% for Q3 2023.

  • Quarterly results put Return on Sales at 504.06% for Q3 2023, down 44901.0% from a year ago — trailing twelve months through Sep 2023 was 17.22% (up 20423.0% YoY), and the annual figure for FY2022 was 136.49%, down 9402.0%.
  • Return on Sales for Q3 2023 was 504.06% at Endonovo Therapeutics, down from 45.66% in the prior quarter.
  • Over the last five years, Return on Sales for ENDV hit a ceiling of 7583.32% in Q4 2021 and a floor of 3886.36% in Q2 2022.
  • Median Return on Sales over the past 5 years was 53.53% (2019), compared with a mean of 71.91%.
  • Biggest five-year swings in Return on Sales: soared 775987bps in 2021 and later plummeted -768979bps in 2022.
  • Endonovo Therapeutics' Return on Sales stood at 38.16% in 2019, then plummeted by -363bps to 176.55% in 2020, then soared by 4395bps to 7583.32% in 2021, then crashed by -101bps to 106.47% in 2022, then tumbled by -373bps to 504.06% in 2023.
  • The last three reported values for Return on Sales were 504.06% (Q3 2023), 45.66% (Q2 2023), and 82.6% (Q1 2023) per Business Quant data.